Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
MPOWERED Trial Open-Label Extension: Long-term Efficacy and Safety Data for Oral Octreotide Capsules in Acromegaly.
Fleseriu M, Molitch M, Dreval A, Pokramovich Y, Bondar I, Poteshkin Y, Macut D, Obermayer-Pietsch B, Gilgun-Sherki Y, Haviv A, Biermasz N, Strasburger CJ. Fleseriu M, et al. Among authors: gilgun sherki y. J Clin Endocrinol Metab. 2023 Nov 17;108(12):3214-3222. doi: 10.1210/clinem/dgad365. J Clin Endocrinol Metab. 2023. PMID: 37319438 Free PMC article. Clinical Trial.
Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial.
Fleseriu M, Dreval A, Bondar I, Vagapova G, Macut D, Pokramovich YG, Molitch ME, Leonova N, Raverot G, Grineva E, Poteshkin YE, Gilgun-Sherki Y, Ludlam WH, Patou G, Haviv A, Gordon MB, Biermasz NR, Melmed S, Strasburger CJ. Fleseriu M, et al. Among authors: gilgun sherki y. Lancet Diabetes Endocrinol. 2022 Feb;10(2):102-111. doi: 10.1016/S2213-8587(21)00296-5. Epub 2021 Dec 22. Lancet Diabetes Endocrinol. 2022. PMID: 34953531 Clinical Trial.
Disease and Treatment-Related Burden in Patients With Acromegaly Who Are Biochemically Controlled on Injectable Somatostatin Receptor Ligands.
Fleseriu M, Molitch M, Dreval A, Biermasz NR, Gordon MB, Crosby RD, Ludlam WH, Haviv A, Gilgun-Sherki Y, Mathias SD. Fleseriu M, et al. Among authors: gilgun sherki y. Front Endocrinol (Lausanne). 2021 Mar 15;12:627711. doi: 10.3389/fendo.2021.627711. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33790860 Free PMC article. Clinical Trial.
Central nervous system effects of the histamine-3 receptor antagonist CEP-26401, in comparison with modafinil and donepezil, after a single dose in a cross-over study in healthy volunteers.
Baakman AC, Zuiker R, van Gerven JMA, Gross N, Yang R, Fetell M, Gershon A, Gilgun-Sherki Y, Hellriegel E, Spiegelstein O. Baakman AC, et al. Among authors: gilgun sherki y. Br J Clin Pharmacol. 2019 May;85(5):970-985. doi: 10.1111/bcp.13885. Epub 2019 Mar 14. Br J Clin Pharmacol. 2019. PMID: 30710391 Free PMC article. Clinical Trial.
Safety, pharmacokinetics, and pharmacodynamics of TV-1380, a novel mutated butyrylcholinesterase treatment for cocaine addiction, after single and multiple intramuscular injections in healthy subjects.
Cohen-Barak O, Wildeman J, van de Wetering J, Hettinga J, Schuilenga-Hut P, Gross A, Clark S, Bassan M, Gilgun-Sherki Y, Mendzelevski B, Spiegelstein O. Cohen-Barak O, et al. Among authors: gilgun sherki y. J Clin Pharmacol. 2015 May;55(5):573-83. doi: 10.1002/jcph.450. Epub 2015 Jan 12. J Clin Pharmacol. 2015. PMID: 25524052 Free PMC article. Clinical Trial.
Erratum to: A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial.
Ziemssen T, Bajenaru OA, Carrá A, de Klippel N, Correia de Sá J, Edland A, Frederiksen JL, Heinzlef O, Karageorgiou KE, Lander Delgado RH, Landtblom AM, Macías Islas MA, Tubridy N, Gilgun-Sherki Y. Ziemssen T, et al. Among authors: gilgun sherki y. J Neurol. 2015 Jan;262(1):248. doi: 10.1007/s00415-014-7565-7. J Neurol. 2015. PMID: 25417969 Free PMC article. No abstract available.
28 results